Feedback / Questions
invikafusp alfa (STAR0602) - Marengo
https://www.prnewswire.com/news-releases/marengo-presents-monotherapy-activity-of-invikafusp-alfa-a-first-in-class-selective-dual-t-cell-agonist-in-pd-1-resistant-gi-tumors-as-a-late-breaking-oral-presentation-at-esmo-gastrointestinal-cancers-congress-2025-302496001.html
Jul 2, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next